Vilazodone submission set for 2009
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Newton, Mass.-based Clinical Data expects to file an NDA for its depression candidate vilazodone in 2009, the firm says Dec. 17. A long-term safety study initiated ahead of schedule in December, along with a second pivotal Phase III trial expected to begin in early 2008, will support the NDA for the dual serotonergic agent, which was licensed from Merck KGaA in September 2004. The second pivotal trial will evaluate a pharmacogenetic test developed in the recently completed first pivotal trial to assist physicians in predicting patients' response to vilazodone...
You may also be interested in...
Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
Subtracting Rx Adds To Perrigo OTC Pipeline
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
When A Single Shot Is A Problem: J&J’s Study Of Two Doses Raises Equality, Distribution Questions
FDA and CDC advisory committee members wonder how to use the single-shot J&J vaccine if an ongoing study shows two doses are better than one.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: